“i was in a daze. i didn’t know what to make of it all,” recalls deb. “we were in the middle of having all the grandchildren come to say their last goodbyes, and then suddenly there’s this phone call. i answered the phone and he told me that my dad was an ideal candidate for a clinical study.”
a revolutionary approach to treating skin cancers
garry’s cancer is a type that mutates readily and rapidly, making it exceptionally difficult to treat by traditional methods. but it’s also particularly responsive to a new class of immunotherapies that have caught the attention of oncologists like dr. butler. “immune checkpoint inhibitors have been in clinical trials for other cancers since the late nineties,” says dr. butler. “we’ve been using this technology for cscc since the mid-2010s, starting with clinical trials.” however, although immunotherapy has been shown to shrink tumours and prolong survival for patients for whom other treatments have failed, not every patient can benefit from it, cautions dr. butler. “it is exciting and unique, but we do need to better understand which specific patients would benefit the most from this treatment.”
though garry had made his peace with dying, he and his family were willing to hang onto this glimmer of hope. “i talked to my dad and he said, ‘well, i’d really rather not die.’ so, that very week, we went to toronto to see dr. butler,” says deb. “two weeks after that he had his first infusion. we could see, right from the very first day of treatment, that there were changes.”
the change was so rapid that it was hard for deb to believe she had her father back, and they could once again look forward with hope. “after his fourth infusion, just weeks after he had been on his deathbed, he went out and bought 24 cedar trees,” deb says. “my dad has always been very strong and very handy. no rock has ever been too heavy for him to move. my daughter nicknamed him superman years ago because of his physical strength, and that title has stuck. he still lives up to it today.”